AI-powered drug development and clinical trials.
23 jobs at Formation Bio
Oct 2018 · Thrive Capital
Nov 2017 · Sequoia Capital
Nov 2016
Investors
Formation Bio · Jun 2026
Significant pipeline milestone: first participant dosed in Phase 1 of BLKR201 after in-licensing the asset from Lynk Pharmaceuticals.
Formation Bio · Nov 2024
Formation Bio, Sanofi, and OpenAI introduced Muse, an AI tool designed to accelerate patient recruitment for clinical trials.
PR Newswire · Jun 2024
Official announcement of Formation Bio’s $372M Series D led by a16z with participation from Sanofi and existing investors.
Reuters · Jun 2024
Reuters coverage of the Series D, noting the round size, key participants, and that the company did not disclose valuation in the announcement.
PR Newswire · Dec 2023
Major corporate milestone: TrialSpark changed its name to Formation Bio and reaffirmed its drug-development platform strategy.